GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Gross Margin %

Prenetics Global (Prenetics Global) Gross Margin % : 49.18% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Prenetics Global's Gross Profit for the three months ended in Dec. 2023 was $2.60 Mil. Prenetics Global's Revenue for the three months ended in Dec. 2023 was $5.28 Mil. Therefore, Prenetics Global's Gross Margin % for the quarter that ended in Dec. 2023 was 49.18%.


The historical rank and industry rank for Prenetics Global's Gross Margin % or its related term are showing as below:

PRE' s Gross Margin % Range Over the Past 10 Years
Min: 27.48   Med: 29.41   Max: 42.45
Current: 42.45


During the past 5 years, the highest Gross Margin % of Prenetics Global was 42.45%. The lowest was 27.48%. And the median was 29.41%.

PRE's Gross Margin % is ranked worse than
53.27% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.155 vs PRE: 42.45

Prenetics Global had a gross margin of 49.18% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Prenetics Global was 0.00% per year.


Prenetics Global Gross Margin % Historical Data

The historical data trend for Prenetics Global's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Gross Margin % Chart

Prenetics Global Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
29.41 40.42 28.75 27.48 40.61

Prenetics Global Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -186.48 44.53 37.50 33.37 49.18

Competitive Comparison of Prenetics Global's Gross Margin %

For the Diagnostics & Research subindustry, Prenetics Global's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prenetics Global's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Prenetics Global's Gross Margin % falls into.



Prenetics Global Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Prenetics Global's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=8.8 / 21.743
=(Revenue - Cost of Goods Sold) / Revenue
=(21.743 - 12.913) / 21.743
=40.61 %

Prenetics Global's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2.6 / 5.277
=(Revenue - Cost of Goods Sold) / Revenue
=(5.277 - 2.682) / 5.277
=49.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Prenetics Global  (NAS:PRE) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Prenetics Global had a gross margin of 49.18% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Prenetics Global Gross Margin % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prenetics Global (Prenetics Global) Business Description

Traded in Other Exchanges
N/A
Address
Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.